Skip to content

Alumis Inc. ALMS Investing Cash Flow

Investing Cash Flow at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
-$131M+73.7%
Amgen logo
AmgenAMGN
-$716M-60.2%
Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
-$14.44M-134%
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
-$11.32M+42.9%
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
$72.12M+67.9%
Immunome logo
ImmunomeIMNM
-$12.02M-336%

Other financials

Income statement

See full
Revenue$1.7M-90.0%
Operating income-$98.4M+3.1%
Net income-$93.1M+6.0%
EPS (diluted)-$0.74+59.3%

Balance sheet

See full
Cash & equivalents$63.9M-50.3%
Total debt$35.7M+1,881%
Total equity$567.0M+237%
Total assets$671.6M+157%

Cash flow

See full
Operating cash flow-$87.1M-8.4%
CapEx$164.0K+343%
Free cash flow-$87.2M-8.5%

Valuation

See full
Market cap$3.17B+739%

Profitability

See full
Operating margin-5,364%
Net margin-2,825.7%
FCF margin-4,487.4%

Returns & leverage

See full
Return on equity-64.6%
Debt / equity0.1×+0.1×
Current ratio7.5×+3.8×

Where this comes from

Reported directly by Alumis Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The official record: Alumis Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alumis Inc.'s investing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Alumis Inc.'s investing cash flow?
Alumis Inc. (ALMS) reported investing cash flow of -$285.69M in Q1 2026.
How has Alumis Inc.'s investing cash flow changed year-over-year?
Alumis Inc.'s investing cash flow decreased by 824.6% year-over-year, from $39.43M to -$285.69M.
What does investing cash flow mean?
Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.